RHYTHM PHARMACEUTICLS ($RYTM) posted quarterly earnings results on Tuesday, November 4th. The company reported earnings of -$0.82 per share, missing estimates of -$0.74 by $0.08. The company also reported revenue of $51,300,000, missing estimates of $51,719,100 by $-419,100.
You can see Quiver Quantitative's $RYTM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
RHYTHM PHARMACEUTICLS Insider Trading Activity
RHYTHM PHARMACEUTICLS insiders have traded $RYTM stock on the open market 30 times in the past 6 months. Of those trades, 0 have been purchases and 30 have been sales.
Here’s a breakdown of recent trading of $RYTM stock by insiders over the last 6 months:
- JOSEPH SHULMAN (Chief Technical Officer) has made 0 purchases and 10 sales selling 59,922 shares for an estimated $6,229,322.
- HUNTER C SMITH (Chief Financial Officer) has made 0 purchases and 5 sales selling 70,208 shares for an estimated $6,094,379.
- DAVID W J MCGIRR has made 0 purchases and 2 sales selling 65,431 shares for an estimated $4,267,494.
- DAVID P MEEKER (President and CEO) has made 0 purchases and 2 sales selling 43,620 shares for an estimated $2,837,333.
- PAMELA J. CRAMER (Chief Human Resources Officer) has made 0 purchases and 5 sales selling 24,123 shares for an estimated $1,810,110.
- CHRISTOPHER PAUL GERMAN (Corporate Controller & CAO) has made 0 purchases and 4 sales selling 7,386 shares for an estimated $589,733.
- ALASTAIR GARFIELD (Chief Scientific Officer) has made 0 purchases and 2 sales selling 1,319 shares for an estimated $85,483.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
RHYTHM PHARMACEUTICLS Hedge Fund Activity
We have seen 129 institutional investors add shares of RHYTHM PHARMACEUTICLS stock to their portfolio, and 111 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRIMECAP MANAGEMENT CO/CA/ removed 909,285 shares (-15.7%) from their portfolio in Q2 2025, for an estimated $57,457,719
- POLAR CAPITAL HOLDINGS PLC added 750,870 shares (+150.2%) to their portfolio in Q2 2025, for an estimated $47,447,475
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 678,760 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $42,890,844
- JPMORGAN CHASE & CO added 639,919 shares (+445.5%) to their portfolio in Q2 2025, for an estimated $40,436,481
- BLACKROCK, INC. removed 587,217 shares (-8.6%) from their portfolio in Q2 2025, for an estimated $37,106,242
- RA CAPITAL MANAGEMENT, L.P. removed 523,053 shares (-8.6%) from their portfolio in Q2 2025, for an estimated $33,051,719
- WOODLINE PARTNERS LP added 514,381 shares (+inf%) to their portfolio in Q2 2025, for an estimated $32,503,735
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
RHYTHM PHARMACEUTICLS Analyst Ratings
Wall Street analysts have issued reports on $RYTM in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 10/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/29/2025
- Morgan Stanley issued a "Overweight" rating on 09/25/2025
- JMP Securities issued a "Market Outperform" rating on 09/25/2025
- Guggenheim issued a "Buy" rating on 08/06/2025
- Canaccord Genuity issued a "Buy" rating on 07/18/2025
- Oppenheimer issued a "Outperform" rating on 07/10/2025
To track analyst ratings and price targets for RHYTHM PHARMACEUTICLS, check out Quiver Quantitative's $RYTM forecast page.
RHYTHM PHARMACEUTICLS Price Targets
Multiple analysts have issued price targets for $RYTM recently. We have seen 12 analysts offer price targets for $RYTM in the last 6 months, with a median target of $110.0.
Here are some recent targets:
- Corinne Jenkins from Goldman Sachs set a target price of $139.0 on 10/17/2025
- Jeffrey Hung from Morgan Stanley set a target price of $129.0 on 10/16/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $110.0 on 09/29/2025
- Jonathan Wolleben from JMP Securities set a target price of $142.0 on 09/25/2025
- Seamus Fernandez from Guggenheim set a target price of $120.0 on 08/06/2025
- Whitney Ijem from Canaccord Genuity set a target price of $105.0 on 07/18/2025
- Tazeen Ahmad from B of A Securities set a target price of $95.0 on 07/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
